Bayer sells testosterone treatment to German company… Leave a comment

Mar­i­anne De Backer

Bay­er AG is all set to sell its testos­terone de­fi­cien­cy treat­ment Nebido to Grü­nen­thal, a Ger­man pain man­age­ment com­pa­ny for about $500 mil­lion.

The deal is ex­pect­ed to close by end of 2022 and could add about $99 mil­lion to Grü­nen­thal’s EBID­TA by 2023.

“This di­vest­ment is part of the on­go­ing trans­for­ma­tion of our phar­ma­ceu­ti­cals busi­ness, which fo­cus­es on key ar­eas of health­care in­no­va­tion,” said Mar­i­anne De Backer, head of strat­e­gy and busi­ness de­vel­op­ment at Bay­er, in a state­ment.

Gabriel Baertschi

Nebido is a long-act­ing in­jectable main­ly used for the treat­ment of male hy­pog­o­nadism — a con­di­tion in which the body does not pro­duce ad­e­quate testos­terone, which is es­sen­tial for mas­cu­line growth and de­vel­op­ment dur­ing pu­ber­ty. Symp­toms of the con­di­tion in­clude loss of sec­ondary sex­u­al char­ac­ter­is­tics such as chest and fa­cial hair, re­duced li­bido or erec­tile dys­func­tion.

The drug is di­rect­ly ad­min­is­tered by a physi­cian every 10-14 weeks.

“One in six men over 50 live with the symp­toms of testos­terone de­fi­cien­cy. Too few of these pa­tients re­ceive ap­pro­pri­ate treat­ment. We are com­mit­ted to fa­cil­i­tat­ing ac­cess to treat­ment for even more pa­tients in need,” Grü­nen­thal CEO Gabriel Baertschi said.

The in­jectable is ap­proved in over 80 coun­tries and is un­der patent pro­tec­tion un­til March 2024 in the EU and un­til May 2027 in the US.

Source